Zachary Bordeaux

Mr. Zachary Bordeaux

Donald and Zucker School of Medicine at Hofstra/Northwell

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JCJustin Choi
Justin Choi
NSNishadh Sutaria
Nishadh Sutaria
YRYoukyung Sophie Roh
Youkyung Sophie Roh
ZBZachary Bordeaux
Zachary Bordeaux
MAMartin P Alphonse
Martin P Alphonse
MKMadan Kwatra
Madan Kwatra
The complexity of atopic dermatitis (AD) continues to present a challenge in the appropriate selection of a mouse model because no single murine model completely recapitulates all aspects of human AD. This has been further complicated by recent evidence of the distinct AD endotypes that are dictated by unique patterns of inflammation involving Th1, Th2, Th17, and Th22 axes. A review of currently used mouse models demonstrates that while all AD mouse models consistently exhibit Th2 inflammation, only some demonstrate concomitant Th17 and/or Th22 induction. As the current understanding of the pathogenic contributions of these unique endotypes and their potential therapeutic roles expands, ongoing efforts to maximize a given mouse model’s homology with human AD necessitates a close evaluation of its distinct immunological signature.

Verified
Journal Article
Open access
PDF file
JCJustin Choi
Justin Choi
ZBZachary Bordeaux
Zachary Bordeaux
JMJaimie McKeel
Jaimie McKeel
CNCory Nanni
Cory Nanni
NSNishadh Sutaria
Nishadh Sutaria
MKMadan Kwatra
Madan Kwatra
Epidermal Growth Factor Receptor (EGFR) is amplified in over 50% of glioblastomas and promotes tumor formation and progression. However, attempts to treat glioblastoma with EGFR tyrosine kinase inhibitors have been unsuccessful thus far. The current standard of care is especially poor in patients with a constitutively active form of EGFR, EGFRvIII, which is associated with shorter survival time. This study examined the effect of GZ17-6.02, a novel anti-cancer agent undergoing phase 1 studies, on two EGFRvIII+ glioblastoma stem cells: D10-0171 and D317. In vitro analyses showed that GZ17-6.02 inhibited the growth of both D10-0171 and D317 cells with IC50 values of 24.84 and 28.28 µg/mL respectively. RNA sequencing and reverse phase protein array analyses revealed that GZ17-6.02 downregulates pathways primarily related to steroid synthesis and cell cycle progression. Interestingly, G17-6.02’s mechanism of action involves the downregulation of the recently identified glioblastoma super-enhancer genes WSCD1, EVOL2, and KLHDC8A. Finally, a subcutaneous xenograft model showed that GZ17-6.02 inhibits glioblastoma growth in vivo. We conclude that GZ17-6.02 is a promising combination drug effective at inhibiting the growth of a subset of glioblastomas and our data warrants further preclinical studies utilizing xenograft models to identify patients that may respond to this drug.

26 September 2022
Verified
Conference Paper
Closed access
ZBZachary Bordeaux
Zachary Bordeaux
In atopic dermatitis (AD), the IL-4/IL-13 receptor system is a promising therapeutic target which consists of the type I (IL4Ra and the common ga | POSTER